Lenvat 10 mg Capsule
Brand Name:
Molecule:
LenvatinibStrength:
Quantity:
Form:
Packaging Type:
Manufacturer/Marketed By:
Natco PharmaCountry of Origin:
₱ 12,500.00
35 in stock
Enquiry Form
Similar Products:
| Product | Manufacturer / Marketed By | Price |
|---|---|---|
| Lenvakast Lenvatinib 10 mg Capsule | Aprazer Healthcare | Ask for Price |
| Lenvima 10 mg Capsule | Eisai Inc | Ask for Price |
| Lenvaxen Lenvatinib 10 mg Capsule | Everest Pharma | Ask for Price |
Description
Lenvat 10 mg Capsule - Detailed Product Information
Lenvat 10 mg Capsule is listed on pinoymeds.ph with detailed information to support careful product review before purchase. This page is designed for informed readers who compare product scope, practical usage context, handling expectations, and ordering workflow in one place. The content below is educational and operational in nature and should not replace clinical diagnosis, direct physician advice, or individualized treatment planning.
Existing product note: Lenvat 10 mg Capsule is a prescription-only medicine that treats certain cancers, including thyroid, kidney, and liver. It contains lenvatinib, which blocks specific proteins that help cancer cells grow and spread throughout the body. By interfering with these proteins, the medicine helps slow down the progression of the disease and may reduce the size of tumors. Natco Pharma Ltd manufactures Lenvat Lenvatinib 10 mg Capsule. Take this medicine strictly under a doctor’s supervision, with regular monitoring during treatment.
Product identity and verification: Confirm product name, concentration or strength, dosage form, pack size, and supplier details before order finalization. Cross-check labels, invoices, and prescribing instructions so ordering records remain accurate across teams and care settings.
Intended usage context: Products in this category are generally used within supervised healthcare workflows. Use should align with prescription intent, clinical eligibility, and local regulation. Where institutional protocols exist, follow those protocols first and document exceptions with responsible clinician approval.
Professional supervision expectations: Product administration decisions should be made by licensed professionals who can review patient-specific history, potential interactions, and contraindication considerations. Independent unsupervised use is discouraged for products requiring clinical oversight.
Dose planning and scheduling discipline: Respect prescribed timing and quantity instructions. Maintain a clear administration log where needed, especially in long-course therapy. Structured logging helps continuity between shifts, tele-consult follow-up, and audit readiness in regulated environments.
Storage and handling fundamentals: Keep products in recommended environmental conditions and away from contamination risks. Confirm storage ranges, humidity sensitivity, and light exposure guidance from the label or package insert. Do not use compromised packaging or uncertain chain-of-custody stock.
Supply continuity and reorder planning: Estimate consumption windows conservatively and reorder early enough to avoid therapy interruptions. For clinical programs or dependent repeat buyers, maintain a rolling buffer strategy and assign ownership for reorder reminders and stock-level checks.
Dispensing communication quality: Provide clear, plain-language instructions and reinforce key safety points at handover. Good counseling includes use schedule, what to monitor, what to avoid, and when to escalate. Repeat-back style communication improves comprehension and adherence outcomes.
Adherence and follow-through management: Strong outcomes often depend on consistent use patterns and practical follow-up. Build routines around reminders, check-ins, and documented milestone reviews. Where adherence barriers exist, address cost, logistics, and understanding gaps proactively.
Safety monitoring and escalation path: If unusual effects, non-response, or tolerance concerns appear, escalate promptly to qualified clinicians. Preserve chronology of events, recent product history, and relevant co-therapy details to accelerate safe decision-making during review.
Quality assurance and documentation standards: Keep records for procurement source, batch identifiers where available, date of receipt, and dispense trail. Reliable documentation supports pharmacovigilance, internal quality systems, and accountable customer support operations.
Compatibility with broader care plans: Product usage should fit into an integrated treatment strategy rather than isolated action. Encourage coordinated review with diagnostic status, current care objectives, and realistic follow-up cadence to reduce fragmentation risks.
Customer support and service operations: For availability checks, timeline commitments, and fulfillment support, contact the support team before checkout completion. Early coordination helps align substitutions, quantity planning, and delivery expectations with real operational capacity.
Responsible information boundaries: Product pages provide structured guidance, not definitive clinical directives. Users should avoid self-adjusting treatment plans based solely on listing text. Final therapeutic decisions belong to licensed clinicians with full case context.
Post-purchase handling and review cycle: After receipt, confirm product condition, correctness, and labeling immediately. Report discrepancies quickly. In ongoing therapy contexts, schedule periodic review so therapy quality, tolerability, and plan fit remain continuously validated.
Product identity and verification: Confirm product name, concentration or strength, dosage form, pack size, and supplier details before order finalization. Cross-check labels, invoices, and prescribing instructions so ordering records remain accurate across teams and care settings.
Intended usage context: Products in this category are generally used within supervised healthcare workflows. Use should align with prescription intent, clinical eligibility, and local regulation. Where institutional protocols exist, follow those protocols first and document exceptions with responsible clinician approval.
Professional supervision expectations: Product administration decisions should be made by licensed professionals who can review patient-specific history, potential interactions, and contraindication considerations. Independent unsupervised use is discouraged for products requiring clinical oversight.
Dose planning and scheduling discipline: Respect prescribed timing and quantity instructions. Maintain a clear administration log where needed, especially in long-course therapy. Structured logging helps continuity between shifts, tele-consult follow-up, and audit readiness in regulated environments.
Storage and handling fundamentals: Keep products in recommended environmental conditions and away from contamination risks. Confirm storage ranges, humidity sensitivity, and light exposure guidance from the label or package insert. Do not use compromised packaging or uncertain chain-of-custody stock.
Supply continuity and reorder planning: Estimate consumption windows conservatively and reorder early enough to avoid therapy interruptions. For clinical programs or dependent repeat buyers, maintain a rolling buffer strategy and assign ownership for reorder reminders and stock-level checks.
Dispensing communication quality: Provide clear, plain-language instructions and reinforce key safety points at handover. Good counseling includes use schedule, what to monitor, what to avoid, and when to escalate. Repeat-back style communication improves comprehension and adherence outcomes.
Adherence and follow-through management: Strong outcomes often depend on consistent use patterns and practical follow-up. Build routines around reminders, check-ins, and documented milestone reviews. Where adherence barriers exist, address cost, logistics, and understanding gaps proactively.
Safety monitoring and escalation path: If unusual effects, non-response, or tolerance concerns appear, escalate promptly to qualified clinicians. Preserve chronology of events, recent product history, and relevant co-therapy details to accelerate safe decision-making during review.
Quality assurance and documentation standards: Keep records for procurement source, batch identifiers where available, date of receipt, and dispense trail. Reliable documentation supports pharmacovigilance, internal quality systems, and accountable customer support operations.
Compatibility with broader care plans: Product usage should fit into an integrated treatment strategy rather than isolated action. Encourage coordinated review with diagnostic status, current care objectives, and realistic follow-up cadence to reduce fragmentation risks.
Important: This information is for product understanding and operational planning only. Always use medicines and related products under guidance from qualified healthcare professionals.
Benefits
- Lenvat 10 mg slows down the growth of cancer cells in the thyroid, kidney, and liver.
- Lenvatinib helps to shrink tumors in affected patients.
- Improves overall survival in patients with advanced cancer.
- It can delay the spread of cancer to other body parts.
- It helps relieve symptoms like pain, pressure, or breathing issues related to tumors.
Indications and Usage
Lenvat 10 mg Capsule is used to treat different types of cancer. Doctors prescribe this medicine when cancer cannot be removed by surgery or has spread to other parts of the body.
It is used to treat:
-
Thyroid Cancer
-
For adults with differentiated thyroid cancer that is progressive (getting worse), and does not respond to radioactive iodine therapy.
-
-
Kidney Cancer (Renal Cell Carcinoma)
-
Used with another medicine called everolimus to treat advanced kidney cancer in people who have already tried one treatment.
-
-
Liver Cancer (Hepatocellular Carcinoma)
-
Used as a first-line treatment for unresectable liver cancer (cancer that cannot be removed by surgery).
-
How it Works
Lenvat 10 mg Capsule contains lenvatinib, a medicine in the tyrosine kinase inhibitor (TKI) group.
What does it do in your body?
- Some cancers grow because of special proteins that tell cancer cells to grow, spread, and make blood vessels.
- These blood vessels bring food and oxygen to the cancer, helping it grow faster.
- Lenvatinib 10 mg blocks these signals, so the cancer cannot grow easily.
What happens when Lenvat 10 mg capsule works?
- It stops the cancer cells from growing.
- It blocks new blood vessels that feed the cancer.
- It helps cancer cells die.
- It can shrink the tumor or stop it from getting bigger.
Which proteins does it block?
Lenvatinib blocks several proteins that are very active in cancer:
- VEGFR (vascular endothelial growth factor receptor)
- FGFR (fibroblast growth factor receptor)
- PDGFR (platelet-derived growth factor receptor)
- RET and KIT (other proteins that help cancer grow)
By blocking these, Lenvat Lenvatinib 10 mg capsules slow or stop the cancer from growing.
Dosage & Administration
Recommended Dosage of Lenvat 10 mg Capsule
- The usual starting dose is 10 mg once per day.
- The dose may change based on:
- Type of cancer
- Body weight
- How your body reacts to the medicine
- Your treating physician must determine the prescribed dosage based on your condition.
How to Take It
- Swallow the capsule whole with a glass of water.
- Do not crush, chew, or open the capsule.
- If you have trouble swallowing, your doctor might tell you how to mix it with water or juice.
Timing
- Take the capsule at the same time every day.
- You can take it with or without food.
Frequency
- The standard dosage is one capsule (10 mg) daily, unless otherwise directed by your doctor.
Missed Dose
- If you forget to take your medicine:
- Take it as soon as you remember.
- If it’s almost time for the next dose, skip the missed one.
- Do not take two doses at the same time.
Overdose Warning
Taking too much of Lenvat 10 mg can be dangerous.
You might get:
- Very high blood pressure
- Severe bleeding
- Liver problems
- Serious side effects
If you take too much by mistake, go to the hospital or call your doctor immediately.
Strengths & Substitutes
| Strength | Alternative Options | ||
| 4 mg | Lenvima 4 mg Capsule | Lenvakast 4mg Capsule | Lenvaxen 4mg Capsule |
| 10 mg | Lenvima 10 mg Capsule | Lenvakast 10 mg Capsule | Lenvaxen 10 mg Capsule |
Side Effects
Common Side Effects of Lenvat 10 mg Capsule:
- High blood pressure
- Diarrhea
- Loss of appetite
- Weight loss
- Headache
- Fatigue
Less Common but Serious Side Effects
- Bleeding problems (nosebleeds, blood in urine or stool)
- Liver function problems
- Skin changes or peeling
- Mouth sores
Severe Reactions – Seek Immediate Help
- Severe chest pain
- Difficulty breathing
- Vision changes
- Fainting or irregular heartbeat
- Signs of allergic reaction (swelling of face/lips, breathing trouble)
Warning and Precaution
Who Should Avoid This Medication
- People with severe liver or kidney problems
- Patients with uncontrolled high blood pressure
- Pregnant women (can harm the unborn baby)
- Breastfeeding mothers may harm their babies.
Drug Interactions
- Avoid using with:
- Amiodarone
- Pimozide
- Haloperidol
- Sotalol
- Thioridazine
Inform your doctor about all medications you are taking.
Food & Lifestyle Considerations
- Avoid alcohol (may worsen side effects).
- Do not drive or operate machinery if you feel dizzy or tired.
- Avoid grapefruit juice, as it may interact with the drug.
Special Warnings
- Requires regular blood pressure monitoring.
- May require liver function tests during treatment.
Use effective birth control during treatment and for at least 1 month after stopping.
Patient Guidance
- Store in a cool, dry place away from sunlight.
- Keep out of reach of children.
- Take with a full glass of water.
- Take it at the same time daily for the best results.
- Do not share this medicine with anyone.
- Do not use after the expiry date.
Clinical Trial & Approvals
- Lenvatinib has been tested in large clinical trials for thyroid, liver, and kidney cancer.
- The SELECT trial (392 patients with thyroid cancer) significantly improved progression-free survival.
- The REFLECT trial (954 patients with liver cancer) showed similar survival benefits to sorafenib but with better tumor response.
- Lenvatinib is FDA-approved and included in NCCN treatment guidelines for relevant cancers.
References
MedlinePlus: Lenvatinib – Drug Information Click here
NCBI Bookshelf: Lenvatinib Summary: Comprehensive medical and clinical profile. Click here
DrugBank: Lenvatinib drug interactions, targets, and mechanisms. Click here
Medscape: Lenvima (Lenvatinib) pharmacology and usage. Click here
Drugs.com: Guidance on lenvatinib usage and risks. Click here
FAQ
Related Products
Related Posts:
No matching posts found.

Rosa Farrell –
It’s very effective for cancer. My husband take it